New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 16, 2012
21:05 EDTILMN, GNOMIllumina confirms failed bid for Complete Genomics
Illumina (ILMN) confirmed in a regulatory filing that it is “Party H” as named in the Schedule 14D-9 filed by Complete Genomics (GNOM) in connection with the tender offer by Beta Acquisition Corporation, a wholly owned subsidiary of BGI-Shenzhen, to purchase all of the outstanding common stock of Complete Genomics. Illumina further confirmed that it submitted proposals to acquire Complete Genomics. Illumina’s most recent proposal, submitted on November 5, included the following terms: a per share cash purchase price of $3.30, which represented approximately a 5% premium over the consideration offered by BGI; financed with cash-on-hand; and without any condition for further due diligence. Complete Genomics called Illumina's offer inadequate.
News For ILMN;GNOM From The Last 14 Days
Check below for free stories on ILMN;GNOM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 9, 2014
08:58 EDTILMNIllumina not targeted by new Chinese regulations, says Janney Capital
Subscribe for More Information
April 7, 2014
07:30 EDTILMNIllumina weakness creates buying opportunity, says Wells Fargo
Wells Fargo believes that the recent decline in Illumina's stock is mostly related to its correlation with biotech indices, and the firm sees this correlation as "a technical rather than a fundamental phenomenon." The firm believes that demand for the company's HiSeq, MiSeq, and HiSeq X instruments are strong, and it now identifies the stock as its top pick in the tools space. It increased its price target on the shares to $170-175 from $155-$160.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use